98 related articles for article (PubMed ID: 25779376)
1. The cytological features of NPM1-mutated acute myeloid leukemia.
Bain BJ; Heller M; Toma S; Pavlů J
Am J Hematol; 2015 Jun; 90(6):560. PubMed ID: 25779376
[No Abstract] [Full Text] [Related]
2. Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia.
Park BG; Chi HS; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
Ann Hematol; 2013 Apr; 92(4):451-7. PubMed ID: 23238897
[TBL] [Abstract][Full Text] [Related]
3. CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation.
Zhu HH; Liu YR; Jiang H; Lu J; Qin YZ; Jiang Q; Bao L; Ruan GR; Jiang B; Huang X
Leuk Res; 2013 Jun; 37(6):624-30. PubMed ID: 23473998
[TBL] [Abstract][Full Text] [Related]
4. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
5. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
[TBL] [Abstract][Full Text] [Related]
6. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
Bains A; Luthra R; Medeiros LJ; Zuo Z
Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
[TBL] [Abstract][Full Text] [Related]
7. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
[TBL] [Abstract][Full Text] [Related]
9. Two novel NPM1 mutations in an acute myeloid leukemia patient transformed from primary myelofibrosis.
Park SH; Chi HS; Shim H; Jang S; Park CJ
Int J Lab Hematol; 2013 Feb; 35(1):e1-3. PubMed ID: 22978565
[No Abstract] [Full Text] [Related]
10. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
Falini B; Martelli MP; Mecucci C; Liso A; Bolli N; Bigerna B; Pucciarini A; Pileri S; Meloni G; Martelli MF; Haferlach T; Schnittger S
Haematologica; 2008 May; 93(5):775-9. PubMed ID: 18367491
[TBL] [Abstract][Full Text] [Related]
11. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).
Liso A; Castiglione F; Cappuccio A; Stracci F; Schlenk RF; Amadori S; Thiede C; Schnittger S; Valk PJ; Döhner K; Martelli MF; Schaich M; Krauter J; Ganser A; Martelli MP; Bolli N; Löwenberg B; Haferlach T; Ehninger G; Mandelli F; Döhner H; Michor F; Falini B
Haematologica; 2008 Aug; 93(8):1219-26. PubMed ID: 18603563
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.
Krönke J; Schlenk RF; Jensen KO; Tschürtz F; Corbacioglu A; Gaidzik VI; Paschka P; Onken S; Eiwen K; Habdank M; Späth D; Lübbert M; Wattad M; Kindler T; Salih HR; Held G; Nachbaur D; von Lilienfeld-Toal M; Germing U; Haase D; Mergenthaler HG; Krauter J; Ganser A; Göhring G; Schlegelberger B; Döhner H; Döhner K
J Clin Oncol; 2011 Jul; 29(19):2709-16. PubMed ID: 21555683
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
Falini B
Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation.
Choschzick M; Bacher U; Ayuk F; Lebeau A
J Clin Pathol; 2010 Jun; 63(6):558-61. PubMed ID: 20360144
[TBL] [Abstract][Full Text] [Related]
15. PU.1 subcellular localization in acute myeloid leukaemia with mutated NPM1.
Pianigiani G; Betti C; Bigerna B; Rossi R; Brunetti L
Br J Haematol; 2020 Jan; 188(1):184-187. PubMed ID: 31764996
[No Abstract] [Full Text] [Related]
16. Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot-Leyden crystals.
Taylor G; Ivey A; Milner B; Grimwade D; Culligan D
Int J Hematol; 2013 Sep; 98(3):267-8. PubMed ID: 23884732
[TBL] [Abstract][Full Text] [Related]
17. Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.
Haferlach T; Bacher U; Alpermann T; Haferlach C; Kern W; Schnittger S
Leuk Res; 2012 Jan; 36(1):51-8. PubMed ID: 21621842
[TBL] [Abstract][Full Text] [Related]
18. Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission.
Chou WC; Peng KY; Lei WC; Ko BS; Tsay W; Kuo CH; Tien HF
Leukemia; 2012 Mar; 26(3):527-9. PubMed ID: 21844873
[No Abstract] [Full Text] [Related]
19. Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia.
Falini B; Brunetti L; Martelli MP
N Engl J Med; 2015 Sep; 373(12):1180-2. PubMed ID: 26376154
[No Abstract] [Full Text] [Related]
20. Therapy-related acute myeloid leukaemia with mutated NPM1: treatment induced or de novo in origin?
Falini B
Leukemia; 2008 May; 22(5):891-2. PubMed ID: 18478020
[No Abstract] [Full Text] [Related]
[Next] [New Search]
